Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study
Nicola Squillace(Azienda Ospedaliera San Gerardo), Paolo Bonfanti(University of California San Diego), Paolo Maggi(Università degli Studi di Enna Kore), Benedetto Maurizio Celesia(Ospedale Garibaldi), Gabriele Forcina(Policlinico Umberto I), Giuseppe Vittorio De Socio(University of Perugia), Filippo Lagi(Policlinico Umberto I), Elena Ricci(Mario Negri Institute for Pharmacological Research), Laura Albini(Gilead Sciences (Italy)), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), E Salomoni(University of Sassari), Giordano Madeddu(University of Sassari), Stefania Piconi(Alessandro Manzoni Hospital), Giovanni Francesco Pellicanò(University of Messina), Antonio Di Biagio, Giancarlo Orofino(Ospedale Amedeo di Savoia), Eleonora Sarchi(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo)
Cited by 4
Related Papers
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells
|The Journal of Immunology|2000|244